Geriatric Assessment and Management in Cancer
Authors: Siri Rostoft, Anita O'Donovan, Pierre Soubeyran, Shabbir M. H. Alibhai, Marije E. Hamaker
Journal: Journal of Clinical Oncology (2021)

Article Tools REVIEW ARTICLES Caring for Older Adults With Cancer Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.21.00089 Journal of Clinical Oncology - published online before print May 27, 2021 PMID: 34043439 Geriatric Assessment and Management in Cancer Siri Rostoft , MD, PhD1,2xSiri RostoftSearch for articles by this author; Anita O'Donovan, PhD3xAnita O'DonovanSearch for articles by this author; Pierre Soubeyran , MD, PhD4xPierre SoubeyranSearch for articles by this author; Shabbir M. H. Alibhai , MD, MSc5,6xShabbir M. H. AlibhaiSearch for articles by this author; and Marije E. Hamaker, MD, PhD7xMarije E. HamakerSearch for articles by this author Show More 1Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway2Institute of Clinical Medicine, University of Oslo, Oslo, Norway3Applied Radiation Therapy Trinity, Trinity St James's Cancer Institute, Trinity College Dublin, Dublin, Ireland4Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, Inserm U1218, Bordeaux, France5Department of Medicine, University of Toronto, Toronto, ON, Canada6Internal Medicine and Geriatrics, University Health Network, Toronto, ON, Canada7Department of Geriatric Medicine, Diakonessenhuis, Utrecht, the Netherlands https://doi.org/10.1200/JCO.21.00089 First Page Full Text PDF Figures and Tables Supplements © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveWhy is geriatric assessment and management (GA&M) recommended for older patients with cancer pretreatment?Knowledge GeneratedOlder patients are heterogeneous, and tailoring cancer treatment to the individual requires weighing risks against benefits in the context of frailty, which is best assessed through geriatric assessment. GA&M can improve prognostication and risk stratification and communication with patients and caregivers, guide treatment adaptations, and provide nononcologic interventions to increase resilience.RelevanceAs increasing evidence shows that GA&M can improve the course of treatment, with less chemotherapy-related toxicity, lower rates of complications after surgery, and improved functional status and quality of life, the challenge is now about implementation into clinical practice.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTGeriatric Assessment and Management in CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Pierre SoubeyranHonoraria: GlaxoSmithKlineConsulting or Advisory Role: Bristol-Myers Squibb, EisaiResearch Funding: RocheTravel, Accommodations, Expenses: Hospira, Teva, Celgene, AstraZenecaShabbir M. H. AlibhaiStock and Other Ownership Interests: ResMedHonoraria: Astellas Scientific and Medical AffairsNo other potential conflicts of interest were reported.